{
    "hands_on_practices": [
        {
            "introduction": "Designing an effective somatic gene therapy requires more than just identifying the causative mutation; it involves a rigorous, multi-parameter optimization process. This practice simulates the real-world task of selecting a guide RNA for a CRISPR-based therapy, where you must balance the need for high on-target efficiency with the critical requirements for precision and safety. By working through this problem , you will learn to apply a principled pipeline to weigh competing factors like cut-to-mutation distance, cleavage efficiency, and off-target risks to make a scientifically sound design choice.",
            "id": "5083258",
            "problem": "A patient presents with sickle cell disease caused by a point mutation in the beta-globin gene (HBB) described by Human Genome Variation Society (HGVS) notation as $c.20A \\to T$, which changes codon $6$ in the coding strand from $GAG$ (glutamate) to $GTG$ (valine). You are tasked with designing a somatic gene therapy strategy to correct this mutation in autologous hematopoietic stem and progenitor cells using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and Streptococcus pyogenes Cas9 (SpCas9), which requires a Protospacer Adjacent Motif (PAM) of the form $NGG$. The repair will use Homology Directed Repair (HDR) with a single-stranded oligodeoxynucleotide (ssODN) donor.\n\nFoundational facts to consider include the Central Dogma of molecular biology (DNA is transcribed to RNA and translated to protein), Watson-Crick base pairing, SpCas9 recognition of $NGG$ PAM on the genomic DNA, and double-strand break repair pathways: Non-Homologous End Joining (NHEJ), which is imprecise, and Homology Directed Repair (HDR), which can precisely incorporate donor-specified changes. SpCas9 makes a blunt cut approximately $3$ base pairs upstream of the PAM along the protospacer strand. HDR efficiency drops as the cut-to-mutation distance increases, and empirically validated on-target efficiency models (for example, the Doench $2016$ model) assign a score to a single guide RNA (sgRNA) reflecting the likelihood of productive cleavage, often scaled between $0$ and $1$. Off-target risk can be approximated by counting predicted genome-wide sites with low-mismatch complementarity.\n\nYou are given a coding-strand sequence window spanning HBB exon $1$ around codon $6$ (wild-type shown; the patient has the $A \\to T$ change at position $c.20$):\n\n$5^{\\prime}$-ATGGTGCACCTGACTCCTGAGGAGAAGTCTGCCGTTACTGCCCTG- $3^{\\prime}$\n\nWithin this window, four candidate sgRNAs (G$1$–G$4$) have been pre-computed. For each, the protospacer, PAM, predicted cut-to-mutation distance $d$ (in base pairs, measured from the cut site to position $c.20$), on-target efficiency score $E$ (unitless, range $0$ to $1$), predicted off-target count $O$ (number of sites with up to $2$ mismatches), and protospacer GC content $G$ (percentage) are listed:\n\n- G$1$: protospacer $5^{\\prime}$-CTCCTGAGGAGAAGTCTGCC- $3^{\\prime}$, PAM $AGG$, $d = 3$, $E = 0.72$, $O = 1$, $G = 55\\%$.\n- G$2$: protospacer $5^{\\prime}$-GCCGTTACTGCCCTGTGGGG- $3^{\\prime}$, PAM $GGG$, $d = 22$, $E = 0.80$, $O = 4$, $G = 65\\%$.\n- G$3$: protospacer $5^{\\prime}$-TGACTCCTGAGGAGAAGTCT- $3^{\\prime}$, PAM $CGG$, $d = 8$, $E = 0.68$, $O = 0$, $G = 40\\%$.\n- G$4$: protospacer $5^{\\prime}$-CCTGACTCCTGTGGAGAAGT- $3^{\\prime}$, PAM $NAG$ (non-canonical), $d = 5$, $E = 0.60$, $O = 6$, $G = 45\\%$.\n\nAssume delivery as ribonucleoprotein complexes into ex vivo cultured cells, and that an ssODN donor can be designed with homology arms of length approximately $60$–$90$ nucleotides on each side of the edit. The aim is to construct and apply a principled guide selection pipeline grounded in the above first principles to maximize the probability of precise HDR correction while minimizing re-cutting and off-target risks.\n\nWhich option best describes a scientifically sound pipeline that starts from PAM availability, imposes a rational constraint on the cut-to-mutation geometry, integrates an on-target efficiency model to rank candidates, includes a design feature to prevent post-repair re-cutting, and then selects the most appropriate candidate from G$1$–G$4$ for correcting $c.20A \\to T$ in HBB?\n\nA. Scan the window for $NGG$ PAMs; restrict to guides whose cut site is near the mutation (on the order of $\\leq 10$ base pairs to favor HDR); use a validated on-target efficiency model to rank; select G$1$; design an ssODN that corrects $c.20T \\to A$ and introduces a synonymous change that abolishes the PAM (or seed) to prevent re-cutting after repair in somatic hematopoietic stem cells timed to $S/G2$ to favor HDR.\n\nB. Select the guide with the highest on-target score regardless of cut-to-mutation distance or PAM type; choose G$2$; rely on Non-Homologous End Joining to produce the correct base change; do not alter the PAM in the donor to preserve the site for possible future editing.\n\nC. Accept non-canonical PAMs to expand candidate space; choose G$4$ because its cut site is close; prioritize embryo-stage germline editing to ensure heritable correction; omit donor design changes to the PAM to avoid introducing additional nucleotide changes.\n\nD. Prioritize zero off-target predictions above all other criteria; choose G$3$; use the ssODN to correct the mutation but avoid altering PAM or seed; deliver in $G0/G1$ phase to minimize cell-cycle perturbations and reduce double-strand breaks.",
            "solution": "### Step 1: Extract Givens\n\nThe problem provides the following information for establishing a gene therapy strategy for sickle cell disease:\n- **Disease and Genetic Basis**: Sickle cell disease caused by a point mutation in the beta-globin gene ($HBB$).\n- **Mutation**: $c.20A \\to T$ in the coding sequence, changing codon $6$ (corresponding to amino acid position $6$, but codon $7$ in the transcript) from $GAG$ (glutamate) to $GTG$ (valine).\n- **Therapeutic Approach**: Somatic gene therapy using autologous hematopoietic stem and progenitor cells (HSPCs).\n- **Editing Machinery**: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) with *Streptococcus pyogenes* Cas9 ($SpCas9$).\n- **$SpCas9$ Requirement**: Recognizes a Protospacer Adjacent Motif (PAM) of the form $NGG$.\n- **Repair Pathway**: Homology Directed Repair (HDR) using a single-stranded oligodeoxynucleotide (ssODN) as a donor template.\n- **Fundamental Principles**: Central Dogma, Watson-Crick base pairing, $SpCas9$ PAM recognition, dsDNA repair pathways (NHEJ vs. HDR), $SpCas9$ cut site ($~3$ base pairs upstream of PAM), and inverse relationship between HDR efficiency and cut-to-mutation distance.\n- **Metrics**: On-target efficiency score $E$ (range $0$ to $1$), predicted off-target count $O$, cut-to-mutation distance $d$.\n- **Target DNA Sequence (coding strand, wild-type)**: $5^{\\prime}$-ATGGTGCACCTGACTCCTGAGGAGAAGTCTGCCGTTACTGCCCTG- $3^{\\prime}$. The mutation is at position $c.20$, which is the `A` in the first `GAG` of the `...GAGGAG...` sequence.\n- **Candidate sgRNAs**:\n    - G$1$: protospacer $5^{\\prime}$-CTCCTGAGGAGAAGTCTGCC- $3^{\\prime}$, PAM $AGG$, $d = 3$ bp, $E = 0.72$, $O = 1$, $G = 55\\%$.\n    - G$2$: protospacer $5^{\\prime}$-GCCGTTACTGCCCTGTGGGG- $3^{\\prime}$, PAM $GGG$, $d = 22$ bp, $E = 0.80$, $O = 4$, $G = 65\\%$.\n    - G$3$: protospacer $5^{\\prime}$-TGACTCCTGAGGAGAAGTCT- $3^{\\prime}$, PAM $CGG$, $d = 8$ bp, $E = 0.68$, $O = 0$, $G = 40\\%$.\n    - G$4$: protospacer $5^{\\prime}$-CCTGACTCCTGTGGAGAAGT- $3^{\\prime}$, PAM $NAG$ (non-canonical), $d = 5$ bp, $E = 0.60$, $O = 6$, $G = 45\\%$.\n- **Objective**: Design a principled guide selection pipeline to maximize precise HDR correction and minimize risks, and use it to select the most appropriate sgRNA from G$1$–G$4$.\n\n### Step 2: Validate Using Extracted Givens\n\n- **Scientific Grounding**: The problem is scientifically sound. It is based on established principles of molecular genetics, CRISPR-Cas9 gene editing, and DNA repair. The specific mutation, gene, disease, and therapeutic concepts (somatic editing, HSPCs, HDR, ssODN) are all factual and represent a current, major area of biomedical research.\n- **Well-Posedness**: The problem is well-posed. It requires the application of a set of defined principles to evaluate a finite number of choices and select the best one. The goal (maximize HDR, minimize risk) is clear, and the data provided ($d, E, O$) allow for a rational, multi-criteria decision-making process.\n- **Objectivity**: The problem is stated in objective, technical language. The data are quantitative and sequence-based.\n- **Flaw Analysis**:\n    1.  **Scientific/Factual Unsoundness**: No major flaws. The description of sickle cell mutation, CRISPR mechanism, and HDR are all correct. The minor ambiguity of \"codon $6$\" is clarified by the precise HGVS notation $c.20A \\to T$ and the codon change $GAG \\to GTG$, which accurately describe the molecular basis of the disease.\n    2.  **Non-Formalizable/Irrelevant**: The problem is fully formalizable and highly relevant to medical genetics and gene therapy.\n    3.  **Incomplete/Contradictory Setup**: There is a potential minor inconsistency between the provided DNA sequence snippet and the listed protospacer/PAM combinations (e.g., the sequence following the G$1$ protospacer in the snippet is not `AGG`). However, in the context of such problems, it is standard to assume that the pre-computed and tabulated data for the candidates (G$1$-G$4$) is the intended ground truth, and the sequence is illustrative. Treating the table as correct allows the core logic of the problem to be addressed. The problem is primarily about evaluating a selection pipeline, not de novo sequence analysis.\n    4.  **Unrealistic/Infeasible**: The conditions and data are realistic for a gene editing scenario. The values for $E$, $O$, and $d$ are plausible.\n    5.  **Ill-Posed/Poorly Structured**: The structure is logical, providing principles first, then data, then a question requiring the integration of both.\n    6.  **Trivial/Tautological**: The problem requires a multi-step reasoning process weighing several competing factors (distance, efficiency, off-targets) and is not trivial.\n\n### Step 3: Verdict and Action\n\nThe problem is **valid**. It presents a realistic and scientifically grounded scenario for designing a gene therapy strategy. Proceeding to solution.\n\n### Derivation of the Optimal Gene Editing Pipeline\n\nTo correct the $c.20A \\to T$ mutation in $HBB$ with high fidelity, a pipeline must be designed to maximize the probability of precise repair via Homology Directed Repair (HDR) while minimizing deleterious outcomes like off-target mutations and on-target errors from Non-Homologous End Joining (NHEJ). The key steps are:\n\n1.  **Enzyme Compatibility**: The specified enzyme is $SpCas9$, which stringently requires an $NGG$ PAM. This is the first, non-negotiable filter. Any sgRNA candidate that does not use an $NGG$ PAM is unsuitable.\n\n2.  **Maximizing HDR Efficiency**: HDR is the desired repair pathway for this precise correction. Its efficiency is critically dependent on the proximity of the DNA double-strand break (DSB) to the site of the desired edit. Efficiency decreases sharply as the cut-to-mutation distance ($d$) increases. Therefore, a rational pipeline must impose a strict constraint on $d$, typically prioritizing candidates where $d \\leq 10$ base pairs.\n\n3.  **On-Target Cleavage**: The guide must be able to direct Cas9 to cleave the target DNA efficiently. The on-target efficiency score ($E$) quantifies this. A higher score is preferable.\n\n4.  **Minimizing Off-Target Risk**: The guide should not direct Cas9 to cut at other locations in the genome. The predicted off-target count ($O$) is a measure of this risk. An ideal guide has $O=0$, and lower values are always better.\n\n5.  **Preventing Post-Repair Re-cutting**: Once HDR successfully corrects the mutation from $T$ back to $A$, the local DNA sequence is restored to wild-type. If this restored sequence is still recognized by the sgRNA/Cas9 complex, it will be re-cut. This can lead to a cycle of cutting and repair, where the error-prone NHEJ pathway might eventually introduce a new, deleterious mutation. To prevent this, the ssODN donor template must be designed to introduce an additional, silent mutation (e.g., a synonymous codon change) that disrupts the PAM or the protospacer \"seed\" sequence, thereby \"blocking\" the site from further editing after successful repair.\n\n6.  **Cellular Context**: HDR is predominantly active during the S and G$2$ phases of the cell cycle when the necessary repair factors are expressed. Thus, delivering the editing reagents to HSPCs when they are actively cycling (synchronized or enriched for $S/G2$) will favor HDR over NHEJ. This is a critical implementation detail.\n\n7.  **Somatic vs. Germline**: The problem specifies a somatic therapy in a single patient. This is distinct from germline editing, which would alter the genomes of eggs or sperm and be heritable, a practice with significant ethical and regulatory barriers.\n\n### Application of the Pipeline to Candidates G$1$–G$4$\n\nWe apply the derived pipeline to the given candidates:\n\n- **G$1$**:\n    - PAM: $AGG$ (valid $NGG$). Pass.\n    - $d = 3$ bp. Excellent, highly favorable for HDR. Pass.\n    - $E = 0.72$. High efficiency. Good.\n    - $O = 1$. Low off-target risk. Acceptable.\n    - **Verdict**: A very strong candidate. The extremely close cut site is a major advantage for maximizing HDR.\n\n- **G$2$**:\n    - PAM: $GGG$ (valid $NGG$). Pass.\n    - $d = 22$ bp. Unacceptably large distance. HDR efficiency will be very low. Fail.\n    - $E = 0.80$. High, but irrelevant given the large $d$.\n    - $O = 4$. Higher risk.\n    - **Verdict**: Poor candidate due to the large cut-to-mutation distance.\n\n- **G$3$**:\n    - PAM: $CGG$ (valid $NGG$). Pass.\n    - $d = 8$ bp. Acceptable distance ($\\leq 10$ bp). Pass.\n    - $E = 0.68$. Good efficiency.\n    - $O = 0$. Ideal, zero predicted off-targets. Excellent.\n    - **Verdict**: A strong candidate, primarily due to its perfect off-target score. However, its cut site is further from the mutation than G$1$'s ($8$ bp vs $3$ bp), which will likely result in lower HDR rates. There is a trade-off between the superior safety profile ($O=0$) of G$3$ and the likely superior HDR efficacy ($d=3$) of G$1$. Given the primary goal is to *maximize correction*, G$1$ is arguably the better choice.\n\n- **G$4$**:\n    - PAM: $NAG$. This is explicitly stated to be non-canonical for $SpCas9$. Fail.\n    - $E = 0.60$. Lower efficiency.\n    - $O = 6$. Highest off-target risk.\n    - **Verdict**: Invalid candidate due to PAM incompatibility with the specified $SpCas9$ enzyme.\n\n**Selection**: Between G$1$ and G$3$, G$1$ provides the best chance of achieving the primary goal—efficient HDR—due to its very small cut-to-mutation distance ($d=3$). While G$3$'s $O=0$ is attractive, an $O=1$ for G$1$ is often considered manageable, pending bioinformatic analysis of the specific off-target site. Therefore, selecting G$1$ is a sound and logical choice that prioritizes efficacy.\n\n### Option-by-Option Analysis\n\n- **A. Scan the window for $NGG$ PAMs; restrict to guides whose cut site is near the mutation (on the order of $\\leq 10$ base pairs to favor HDR); use a validated on-target efficiency model to rank; select G$1$; design an ssODN that corrects $c.20T \\to A$ and introduces a synonymous change that abolishes the PAM (or seed) to prevent re-cutting after repair in somatic hematopoietic stem cells timed to $S/G2$ to favor HDR.**\n    - This option describes a pipeline that perfectly matches our derived ideal strategy. It correctly identifies the PAM requirement, the importance of a small $d$, the use of efficiency scores, the selection of the most suitable candidate (G$1$), the critical need for a PAM-blocking silent mutation in the donor, the correct cell type (somatic HSPCs), and the optimal cell-cycle timing ($S/G2$). Every step is scientifically sound and state-of-the-art.\n    - **Verdict: Correct.**\n\n- **B. Select the guide with the highest on-target score regardless of cut-to-mutation distance or PAM type; choose G$2$; rely on Non-Homologous End Joining to produce the correct base change; do not alter the PAM in the donor to preserve the site for possible future editing.**\n    - This option is fundamentally flawed. (1) It ignores the critical cut-to-mutation distance, leading to the selection of G$2$ ($d=22$ bp) where HDR would be minimal. (2) It incorrectly suggests NHEJ can produce a specific base change; NHEJ is error-prone and creates indels, it cannot perform a precise $T \\to A$ substitution. (3) It incorrectly advises against altering the PAM, which would lead to destructive re-cutting of the corrected allele.\n    - **Verdict: Incorrect.**\n\n- **C. Accept non-canonical PAMs to expand candidate space; choose G$4$ because its cut site is close; prioritize embryo-stage germline editing to ensure heritable correction; omit donor design changes to the PAM to avoid introducing additional nucleotide changes.**\n    - This option is flawed. (1) It uses a non-canonical PAM with standard $SpCas9$, which is incorrect. (2) It proposes germline editing, which contradicts the problem's premise of somatic therapy and is ethically controversial. (3) It omits the PAM block, a poor design choice. (4) The chosen guide, G$4$, has the highest off-target liability ($O=6$).\n    - **Verdict: Incorrect.**\n\n- **D. Prioritize zero off-target predictions above all other criteria; choose G$3$; use the ssODN to correct the mutation but avoid altering PAM or seed; deliver in $G0/G1$ phase to minimize cell-cycle perturbations and reduce double-strand breaks.**\n    - This option has multiple serious flaws. (1) While prioritizing $O=0$ is a valid safety strategy, the pipeline is crippled by its other elements. (2) It advises against a PAM block, which is a major design error. (3) It recommends delivery in $G0/G1$, which is the wrong phase of the cell cycle for HDR. Targeting $G0/G1$ would strongly favor NHEJ, defeating the purpose of precision editing.\n    - **Verdict: Incorrect.**",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "The gene editor's toolbox is rapidly expanding, but choosing the right tool for a specific job is a critical decision. This exercise  moves beyond using a single technology and challenges you to quantitatively compare two major approaches: traditional CRISPR-Cas9 with Homology Directed Repair (HDR) and the newer technique of base editing. You will discover how the fundamental biology of the target cell—in this case, its post-mitotic state—can render one strategy profoundly more effective than another, reinforcing the importance of context in therapeutic design.",
            "id": "5083253",
            "problem": "A pathogenic single-nucleotide variant in a post-mitotic neuron changes a guanine ($G$) to adenine ($A$) at a disease-relevant locus. You are considering two somatic gene therapy strategies to restore the wild-type base: Homology Directed Repair (HDR) using clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein $9$ (CRISPR-Cas9) with a donor template, and a programmable Adenine Base Editor (ABE) that converts target adenine to guanine without making a double-strand break. The cell type is strictly post-mitotic. Use the following scientifically reasonable assumptions, stated as per-cell probabilities or fractions, to quantify the expected fraction of correctly edited, indel-free cells for each approach.\n\nFacts to use as the fundamental base:\n- HDR is restricted to the synthesis ($S$) and gap $2$ ($G2$) phases and is negligibly active in strictly post-mitotic cells; in such cells, double-strand breaks are predominantly repaired by Non-Homologous End Joining (NHEJ), which does not use a donor template and frequently introduces insertions or deletions.\n- Base editors do not require double-strand breaks and can operate in post-mitotic cells by coupling deamination chemistry to endogenous base excision and mismatch repair.\n\nAssume the following quantities:\n- For ABE delivery via Adeno-Associated Virus (AAV), the fraction of target cells receiving functional editor components is $p_{\\text{del,ABE}} = 0.65$.\n- The probability that the guide ribonucleic acid (RNA) correctly binds and positions the target $A$ within the effective editing window is $p_{\\text{on}} = 0.90$.\n- Conditional on correct positioning, the probability that the deamination and subsequent repair produce the desired $A \\rightarrow G$ outcome at the target base is $p_{\\text{chem}} = 0.70$.\n- The probability that no bystander edits occur in the window (that is, the product is the single desired change only) is $p_{\\text{pure}} = 0.80$.\n- The probability that the edit occurs without any insertion or deletion is $p_{\\text{noindel,ABE}} = 0.98$.\n- The probability that the cell remains viable after editing is $p_{\\text{viab,ABE}} = 0.95$.\n\n- For HDR using CRISPR-Cas9 with a donor template:\n  - The fraction of target cells receiving both Cas9 and donor template is $p_{\\text{del,HDR}} = 0.55$.\n  - The probability of creating a double-strand break at the target is $p_{\\text{DSB}} = 0.80$.\n  - The probability that the donor template is available in the nucleus at the time of repair is $p_{\\text{donor}} = 0.50$.\n  - In strictly post-mitotic cells, the probability that the break is repaired via HDR (rather than Non-Homologous End Joining) is $p_{\\text{HDR}} = 0.010$.\n  - Conditional on HDR, the probability that the correct single-base change is incorporated without additional sequence changes is $p_{\\text{correct}} = 0.90$.\n  - The probability that the cell remains viable after editing is $p_{\\text{viab,HDR}} = 0.80$.\n\nDefine the expected yield for each approach as the fraction of target cells that end up with exactly the desired single-base correction and no insertion or deletion, multiplied by viability. Compute the fold difference in expected yield, defined as the ABE expected yield divided by the HDR expected yield. Express your final answer as a dimensionless number. Round your answer to three significant figures.",
            "solution": "The problem requires a quantitative comparison of the expected yield of two gene editing strategies, Adenine Base Editing (ABE) and Homology Directed Repair (HDR), in post-mitotic cells. The expected yield ($Y$) is defined as the fraction of the initial cell population that is successfully edited to the desired single-base correction, is free of indels, and remains viable. This can be calculated by multiplying the probabilities of all sequential events required for a successful outcome.\n\nFirst, we calculate the expected yield for the ABE approach ($Y_{\\text{ABE}}$). A successful outcome requires delivery of the editor, correct binding, successful chemical conversion, purity (no bystander edits), absence of indels, and cell viability. The total yield is the product of these probabilities:\n$$Y_{\\text{ABE}} = p_{\\text{del,ABE}} \\times p_{\\text{on}} \\times p_{\\text{chem}} \\times p_{\\text{pure}} \\times p_{\\text{noindel,ABE}} \\times p_{\\text{viab,ABE}}$$\nSubstituting the given values:\n$$Y_{\\text{ABE}} = (0.65) \\times (0.90) \\times (0.70) \\times (0.80) \\times (0.98) \\times (0.95)$$\n$$Y_{\\text{ABE}} = 0.3049956$$\n\nNext, we calculate the expected yield for the HDR approach ($Y_{\\text{HDR}}$). A successful outcome requires co-delivery of Cas9 and a donor, creation of a double-strand break (DSB), availability of the donor, repair via the HDR pathway, correct incorporation of the edit, and cell viability. The problem states that HDR is negligibly active in post-mitotic cells ($p_{\\text{HDR}} = 0.010$), which is the key limiting factor. The total yield is the product of these probabilities:\n$$Y_{\\text{HDR}} = p_{\\text{del,HDR}} \\times p_{\\text{DSB}} \\times p_{\\text{donor}} \\times p_{\\text{HDR}} \\times p_{\\text{correct}} \\times p_{\\text{viab,HDR}}$$\nSubstituting the given values:\n$$Y_{\\text{HDR}} = (0.55) \\times (0.80) \\times (0.50) \\times (0.010) \\times (0.90) \\times (0.80)$$\n$$Y_{\\text{HDR}} = 0.001584$$\n\nFinally, we compute the fold difference in expected yield, defined as the ratio of the ABE yield to the HDR yield.\n$$\\text{Fold Difference} = \\frac{Y_{\\text{ABE}}}{Y_{\\text{HDR}}}$$\n$$\\text{Fold Difference} = \\frac{0.3049956}{0.001584} \\approx 192.547727$$\nRounding the result to three significant figures gives:\n$$\\text{Fold Difference} \\approx 193$$\nThis large difference highlights the profound advantage of using a cell cycle-independent technology like base editing over traditional HDR for gene correction in non-dividing cells such as neurons.",
            "answer": "$$ \\boxed{193} $$"
        },
        {
            "introduction": "While somatic gene therapy affects only the individual patient, germline editing introduces heritable changes that can be passed to subsequent generations, with population-level consequences. This problem  shifts our focus from the cellular to the population scale, asking you to apply fundamental principles of Mendelian inheritance and population genetics to model the transmission of an edited allele. This practice is crucial for understanding the long-term impact of germline modifications and provides a quantitative framework for the ethical discussions surrounding them.",
            "id": "5083240",
            "problem": "In a large, randomly mating (panmictic) human population at equilibrium, consider a single autosomal locus with two alleles: an edited allele $E$ and the wild-type allele $e$. A germline gene therapy procedure renders one individual heterozygous at this locus, with genotype $E/e$. Assume no selection, no new mutation, no migration, and equal contribution of gametes across sexes. Assume complete penetrance (genotype fully determines phenotype) but that phenotype does not influence mate choice. Let the current allele frequency of $E$ in the mating pool, excluding the treated individual, be $p$, with $0 \\le p \\le 1$.\n\nUsing only fundamental principles of heredity and population genetics, derive the expected probability that a randomly conceived autosomal offspring of this treated individual carries at least one copy of the edited allele $E$. Express your final answer as a closed-form expression in terms of $p$. No rounding is required, and no units are needed.",
            "solution": "The problem asks for the probability that an offspring of a specific heterozygous individual and a random mate carries at least one copy of the edited allele $E$.\n\nLet the treated individual be Parent 1. Parent 1 has the genotype $E/e$. According to Mendelian segregation, Parent 1 will produce gametes with allele $E$ and allele $e$ with equal probability:\n*   Probability of Parent 1's gamete being $E$: $P(\\text{gamete}_1 = E) = \\frac{1}{2}$\n*   Probability of Parent 1's gamete being $e$: $P(\\text{gamete}_1 = e) = \\frac{1}{2}$\n\nLet the random mate be Parent 2. Parent 2 is drawn from a large, panmictic population where the allele frequency of $E$ is $p$ and the allele frequency of $e$ is $1-p$. The probability that a random gamete from this population carries a specific allele is equal to that allele's frequency.\n*   Probability of Parent 2's gamete being $E$: $P(\\text{gamete}_2 = E) = p$\n*   Probability of Parent 2's gamete being $e$: $P(\\text{gamete}_2 = e) = 1-p$\n\nWe want to find the probability that the offspring has at least one $E$ allele, which means the offspring's genotype is either $E/E$ or $E/e$. It is simpler to calculate the probability of the complementary event—the offspring having no $E$ allele (genotype $e/e$)—and subtract this from 1.\n\nThe offspring's genotype will be $e/e$ if and only if it inherits an $e$ allele from Parent 1 AND an $e$ allele from Parent 2. Since the selection of gametes is independent, we multiply their probabilities:\n$$P(\\text{offspring is } e/e) = P(\\text{gamete}_1 = e) \\times P(\\text{gamete}_2 = e)$$\nSubstituting the known probabilities:\n$$P(\\text{offspring is } e/e) = \\frac{1}{2} \\times (1-p) = \\frac{1-p}{2}$$\n\nThe probability of the offspring having at least one $E$ allele is therefore:\n$$P(\\text{offspring has } \\ge 1 E) = 1 - P(\\text{offspring is } e/e)$$\n$$P(\\text{offspring has } \\ge 1 E) = 1 - \\frac{1-p}{2}$$\nTo simplify, we use a common denominator:\n$$P(\\text{offspring has } \\ge 1 E) = \\frac{2}{2} - \\frac{1-p}{2} = \\frac{2 - (1-p)}{2} = \\frac{2 - 1 + p}{2}$$\n$$P(\\text{offspring has } \\ge 1 E) = \\frac{1+p}{2}$$\n\nAn alternative method is to sum the probabilities of the mutually exclusive events that result in an offspring with at least one $E$ allele:\n1.  Parent 1 contributes an $E$ gamete (probability $\\frac{1}{2}$). The offspring will have an $E$ allele regardless of Parent 2's contribution.\n2.  Parent 1 contributes an $e$ gamete (probability $\\frac{1}{2}$) AND Parent 2 contributes an $E$ gamete (probability $p$). The probability of this path is $\\frac{1}{2} \\times p = \\frac{p}{2}$.\n\nThe total probability is the sum of these two paths:\n$$P(\\text{offspring has } \\ge 1 E) = \\frac{1}{2} + \\frac{p}{2} = \\frac{1+p}{2}$$\nBoth methods yield the same correct result.",
            "answer": "$$\n\\boxed{\\frac{1+p}{2}}\n$$"
        }
    ]
}